

TABLE S1 Frequency of subjects experiencing TEAEs^a and number of events summarized per treatment (Trial 1)

MedDRA ^b system organ class ^c	MedDRA preferred term ^c	Statistic	MHAA4549A				Overall	Placebo
			1.5 mg/kg	5 mg/kg	15 mg/kg	45 mg/kg		
Number of subjects dosed		N	4	4	4	4	16	5
Number of TEAEs		E	4	7	4	4	19	4
Number of subjects ^d with TEAEs		n (%)	2 (50)	3 (75)	2 (50)	3 (75)	10 (62.5)	3 (60)
Nervous system disorders		n (%) E	0	2 (50) 2	1 (25) 1	2 (50) 2	5 (31.3) 5	1 (20) 1
Headache		n (%) E	0	2 (50) 2	1 (25) 1	1 (25) 1	4 (25) 4	1 (20) 1
Dysgeusia		n (%) E	0	0	0	1 (25) 1	1 (6.3) 1	0
Gastrointestinal disorders		n (%) E	0	2 (50) 2	1 (25) 3	1 (25) 1	4 (25) 6	0
Abdominal pain		n (%) E	0	0	0	1 (25) 1	1 (6.3) 1	0
Abdominal pain upper		n (%) E	0	1 (25) 1	0	0	1 (6.3) 1	0
Eructation		n (%) E	0	0	1 (25) 1	0	1 (6.3) 1	0
Flatulence		n (%) E	0	0	1 (25) 1	0	1 (6.3) 1	0
Nausea		n (%) E	0	0	1 (25) 1	0	1 (6.3) 1	0
Toothache		n (%) E	0	1 (25) 1	0	0	1 (6.3) 1	0
Respiratory, thoracic and mediastinal disorders		n (%) E	1 (25) 2	1 (25) 2	0	1 (25) 1	3 (18.8) 5	0
Oropharyngeal pain		n (%) E	1 (25) 1	0	0	2 (25) 1	2 (12.5) 2	0
Cough		n (%) E	0	1 (25) 1	0	0	1 (6.3) 1	0
Nasal congestion		n (%) E	1 (25) 1	0	0	0	1 (6.3) 1	0
Rhinorrhoea		n (%) E	0	1 (25) 1	0	0	1 (6.3) 1	0
Injury, poisoning and procedural complications		n (%) E	2 (50) 2	0	0	0	2 (12.5) 2	1 (20) 1
Ligament sprain		n (%) E	1 (25) 1	0	0	0	1 (6.3) 1	0
Tooth fracture		n (%) E	1 (25) 1	0	0	0	1 (6.3) 1	0
Burns second degree		n (%) E	0	0	0	0	0	1 (20) 1
Investigations		n (%) E	0	1 (25) 1	0	0	1 (6.3) 1	1 (20) 1
Alanine aminotransferase increased		n (%) E	0	1 (25) 1	0	0	1 (6.3) 1	0
Blood creatine phosphokinase increased		n (%) E	0	0	0	0	0	1 (20) 1
Skin and subcutaneous tissue disorders		n (%) E	0	0	0	0	0	1 (20) 1
Urticaria		n (%) E	0	0	0	0	0	1 (20) 1

^aTEAE, treatment-emergent adverse event^bMedDRA, Medical Dictionary for Regulatory Activities; MedDRA Version 16.0^cSystem organ class and preferred term are presented in descending order of overall incidence rate considering all active subjects.^dEach subject could only contribute once to each of the incidence rates, regardless of the number of occurrences.

TABLE S2 Frequency of subjects experiencing TEAEs^a and number of events summarized per treatment (Trial 2)

MedDRA ^b system organ class ^c	MedDRA preferred term ^c	Statistic	MHAA4549A			
			8400 mg	10800 mg	Overall	Placebo
Number of subjects dosed		N	4	4	8	6
Number of TEAEs		E	15	9	24	10
Number of subjects ^d with TEAEs		n (%)	3 (75)	4 (100)	7 (87.5)	5 (83.3)
Nervous system disorders		n (%) E	3 (75) 3	1 (25) 1	4 (50) 4	2 (33.3) 4
Headache		n (%) E	3 (75) 3	1 (25) 1	4 (50) 4	2 (33.3) 4
Infections and infestations		n (%) E	1 (25) 3	2 (50) 2	3 (37.5) 5	2 (33.3) 3
Nasopharyngitis		n (%) E	1 (25) 1	2 (50) 2	3 (37.5) 3	2 (33.3) 3
Bacterial infection		n (%) E	1 (25) 2	0	1 (12.5) 2	0
General disorders and administration site conditions		n (%) E	2 (50) 2	1 (25) 1	3 (37.5) 3	0
Asthenia		n (%) E	0	1 (25) 1	1 (12.5) 1	0
Fatigue		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Peripheral swelling		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Gastrointestinal disorders		n (%) E	1 (25) 2	1 (25) 1	2 (25) 3	0
Abdominal discomfort		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Faeces soft		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Nausea		n (%) E	0	1 (25) 1	1 (12.5) 1	0
Respiratory, thoracic and mediastinal disorders		n (%) E	1 (25) 1	1 (25) 1	2 (25) 2	2 (33.3) 2
Nasal congestion		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Nasal discomfort		n (%) E	0	1 (25) 1	1 (12.5) 1	0
Oropharyngeal discomfort		n (%) E	0	0	0	1 (16.7) 1
Rhinorrhoea		n (%) E	0	0	0	1 (16.7) 1
Investigations		n (%) E	0	1 (25) 2	1 (12.5) 2	0
Blood creatine phosphokinase increased		n (%) E	0	1 (25) 2	1 (12.5) 2	0
Reproductive system and breast disorders		n (%) E	1 (25) 2	0	1 (12.5) 2	0
Metrorrhagia		n (%) E	1 (25) 2	0	1 (12.5) 2	0
Eye disorders		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Conjunctival hyperaemia		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Injury, poisoning and procedural complications		n (%) E	0	1 (25) 1	1 (12.5) 1	0
Contusion		n (%) E	0	1 (25) 1	1 (12.5) 1	0
Skin and subcutaneous tissue disorders		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Pruritus		n (%) E	1 (25) 1	0	1 (12.5) 1	0
Musculoskeletal and connective tissue disorders		n (%) E	0	0	0	1 (16.7) 1
Arthralgia		n (%) E	0	0	0	1 (16.7) 1

^aTEAE, treatment-emergent adverse event.

^bMedDRA, Medical Dictionary for Regulatory Activities; MedDRA Version 17.1.

^cSystem organ class and preferred term are presented in descending order of overall incidence rate considering all active subjects.

^dEach subject could only contribute once to each of the incidence rates, regardless of the number of occurrences.